The global aquaculture vaccines market size was estimated to be USD 0.412 billion in 2023 and is expected to reach at USD 1.01 billion by 2034 with a CAGR of 8.47% during the forecast period 2024-2034. Increased aquaculture production, a rising appetite for food products derived from aquatic animals, the implementation of effective & safe vaccination programs, a higher incidence of bacterial & viral infections, continuous advancements, growing introduction of new aquaculture vaccines, rising prevalence of diseases in aquatic animals, an elevated demand for various products from aquatic animals such as oil, protein powders, caviar, & meat, and an increase in collaborative efforts among market entities for the distribution of aquaculture vaccines are some of the key factors boosting the market growth.
An increase in collaborative efforts among market entities for the distribution of aquaculture vaccines is predicted to boost the market growth during the forecast period. For instance, in January 2023, ScaleAQ collaborated with fish vaccination specialist Skala Maskon by this the firm intends to broaden its value chain to become a whole supplier and partner to the farming sector. This acquisition represents a strategic and substantial investment that consolidates a diverse and robust expertise landscape within the supply business of the aquaculture sector. It will boost the company's position as a holistic supplier of vital infrastructure for the agricultural industry.
By product, inactivated vaccines was the highest revenue-grossing segment in the global aquaculture vaccines market in 2023 owing to the rising partnerships among market leaders. The production of inactivated bacterial and viral vaccines involves cultivating significant quantities of the disease-causing pathogens through fermentation. Subsequently, inactivating agents like formalin are added to eliminate all microorganisms. Despite the inactivation process, these organisms still provoke an immune response because they maintain their fundamental shape, original antigenic features, and structure. For instance, in June 2022, Cal Poly Venture has revealed its involvement in a Series A funding round for Mazen Animal Health Inc., contributing to a total of USD 12 million. Mazen Animal Health is dedicated to the development, distribution, and commercialization of cutting-edge biological vaccines and medicines. Additionally, recombinant vaccines is predicted to grow at the fastest CAGR during the forecast period. Recombinant vaccines are capable of eliciting a robust immune response in vaccinated fish by mimicking infections that occur naturally. Additionally, the production of recombinant vaccines on a large scale for commercial purposes is more straightforward.
By route of administration, injected was the highest revenue-grossing segment in the global aquaculture vaccines market in 2023 owing to the growing mergers & acquisitions within major companies. The administration of injection vaccines is an effective means of triggering an antibody response in fish. These injections can be either intramuscular or intraperitoneal. While most aquaculture vaccinations protect against bacterial infections, they can be administered through injections or oral methods, including intraperitoneal or intramuscular routes. For instance, in September 2022, Zoetis Inc. has announced the successful finalization of its acquisition of Jurox, a privately owned animal health company specializing in the development, manufacturing, and marketing of a diverse range of pharmaceuticals for the veterinary treatment of both livestock and companion animals. Additionally, oral is predicted to grow at the fastest CAGR during the forecast period. Oral vaccination offers numerous benefits compared to alternative administration methods. It is a non-invasive process that eliminates the need for direct handling of the fish, making it a convenient and easily applicable method suitable for mass immunization. These advantages contribute to the expansion of the oral vaccination segment.
By application, bacterial was the highest revenue-grossing segment in the global aquaculture vaccines market in 2023 owing to surge in investment by leading market entities. In aquatic organisms, vaccines developed through cost-effective and efficient techniques, particularly utilizing advanced molecular technology, can effectively treat disease-causing microorganisms. For instance, in March 29, 2022, The European Union (EU) and the European Investment Fund (EIF) have forged a partnership and launched a dedicated equity initiative amounting to US$ 539.5 million for the blue economy and aquaculture under InvestEU. This announcement took place during the BlueInvest days 2022 in Brussels. The BlueInvest initiative is set to extend its operations beyond 2022, continuing until 2026. Additionally, viral is predicted to grow at the fastest CAGR during the forecast period owing to the rise in viral infections, escalating research and development endeavors, and governmental backing for the development of aquaculture vaccines are notable trends in the industry.
North America region is anticipated for the highest revenue share during the forecast period owing to the government & private sector initiatives are providing support, increasing human concerns regarding antimicrobial resistance, the presence of key players is also contributing to these efforts, and increase in funding for research activities. For instance, in January 2022, Benchmark Animal Health and Cermaq Group AS secured NOK 4.2 million in funding from the Research Council of Norway. The funding is designated to support their joint research project aimed at developing a vaccine targeting salmon diseases caused by Tenacibaculum bacteria. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the aquaculture industry is experiencing significant growth, propelled by supportive government initiatives, the presence of suitable water resources in numerous countries, a shift towards sustainable aquaculture practices, and a notable increase in partnerships and collaborations among market players focused on developing novel vaccines. For instance, in November 2022, Indian Immunologicals Ltd. (IIL), headquartered in Hyderabad, has joined forces with the Central Institute of Fisheries Education (CIFE) to collaboratively advance the commercial development of India's inaugural fish vaccine.
An increase in collaborative efforts among market entities for the distribution of aquaculture vaccines is predicted to boost the market growth during the forecast period. For instance, in January 2023, ScaleAQ collaborated with fish vaccination specialist Skala Maskon by this the firm intends to broaden its value chain to become a whole supplier and partner to the farming sector. This acquisition represents a strategic and substantial investment that consolidates a diverse and robust expertise landscape within the supply business of the aquaculture sector. It will boost the company's position as a holistic supplier of vital infrastructure for the agricultural industry.
By product, inactivated vaccines was the highest revenue-grossing segment in the global aquaculture vaccines market in 2023 owing to the rising partnerships among market leaders. The production of inactivated bacterial and viral vaccines involves cultivating significant quantities of the disease-causing pathogens through fermentation. Subsequently, inactivating agents like formalin are added to eliminate all microorganisms. Despite the inactivation process, these organisms still provoke an immune response because they maintain their fundamental shape, original antigenic features, and structure. For instance, in June 2022, Cal Poly Venture has revealed its involvement in a Series A funding round for Mazen Animal Health Inc., contributing to a total of USD 12 million. Mazen Animal Health is dedicated to the development, distribution, and commercialization of cutting-edge biological vaccines and medicines. Additionally, recombinant vaccines is predicted to grow at the fastest CAGR during the forecast period. Recombinant vaccines are capable of eliciting a robust immune response in vaccinated fish by mimicking infections that occur naturally. Additionally, the production of recombinant vaccines on a large scale for commercial purposes is more straightforward.
By route of administration, injected was the highest revenue-grossing segment in the global aquaculture vaccines market in 2023 owing to the growing mergers & acquisitions within major companies. The administration of injection vaccines is an effective means of triggering an antibody response in fish. These injections can be either intramuscular or intraperitoneal. While most aquaculture vaccinations protect against bacterial infections, they can be administered through injections or oral methods, including intraperitoneal or intramuscular routes. For instance, in September 2022, Zoetis Inc. has announced the successful finalization of its acquisition of Jurox, a privately owned animal health company specializing in the development, manufacturing, and marketing of a diverse range of pharmaceuticals for the veterinary treatment of both livestock and companion animals. Additionally, oral is predicted to grow at the fastest CAGR during the forecast period. Oral vaccination offers numerous benefits compared to alternative administration methods. It is a non-invasive process that eliminates the need for direct handling of the fish, making it a convenient and easily applicable method suitable for mass immunization. These advantages contribute to the expansion of the oral vaccination segment.
By application, bacterial was the highest revenue-grossing segment in the global aquaculture vaccines market in 2023 owing to surge in investment by leading market entities. In aquatic organisms, vaccines developed through cost-effective and efficient techniques, particularly utilizing advanced molecular technology, can effectively treat disease-causing microorganisms. For instance, in March 29, 2022, The European Union (EU) and the European Investment Fund (EIF) have forged a partnership and launched a dedicated equity initiative amounting to US$ 539.5 million for the blue economy and aquaculture under InvestEU. This announcement took place during the BlueInvest days 2022 in Brussels. The BlueInvest initiative is set to extend its operations beyond 2022, continuing until 2026. Additionally, viral is predicted to grow at the fastest CAGR during the forecast period owing to the rise in viral infections, escalating research and development endeavors, and governmental backing for the development of aquaculture vaccines are notable trends in the industry.
North America region is anticipated for the highest revenue share during the forecast period owing to the government & private sector initiatives are providing support, increasing human concerns regarding antimicrobial resistance, the presence of key players is also contributing to these efforts, and increase in funding for research activities. For instance, in January 2022, Benchmark Animal Health and Cermaq Group AS secured NOK 4.2 million in funding from the Research Council of Norway. The funding is designated to support their joint research project aimed at developing a vaccine targeting salmon diseases caused by Tenacibaculum bacteria. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the aquaculture industry is experiencing significant growth, propelled by supportive government initiatives, the presence of suitable water resources in numerous countries, a shift towards sustainable aquaculture practices, and a notable increase in partnerships and collaborations among market players focused on developing novel vaccines. For instance, in November 2022, Indian Immunologicals Ltd. (IIL), headquartered in Hyderabad, has joined forces with the Central Institute of Fisheries Education (CIFE) to collaboratively advance the commercial development of India's inaugural fish vaccine.
Segmentation: Aquaculture Vaccines Market Report 2023 - 2034
Aquaculture Vaccines Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Attenuated Live Vaccines
- Recombinant Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- DNA Vaccines
Aquaculture Vaccines Market Analysis & Forecast by Route Of Administration 2023 - 2034 (Revenue USD Bn)
- Immersion & Spray
- Injected
- Oral
Aquaculture Vaccines Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Viral
- Parasitic
- Bacterial
Aquaculture Vaccines Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Aquaculture Vaccines Market: Product Estimates & Trend Analysis
8. Aquaculture Vaccines Market: Route of Administration Estimates & Trend Analysis
9. Aquaculture Vaccines Market: Application Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Aquaculture Vaccines Market
12. Europe Global Aquaculture Vaccines Market
13. Asia Pacific Global Aquaculture Vaccines Market
14. Latin America Global Aquaculture Vaccines Market
15. MEA Global Aquaculture Vaccines Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Kyoto Biken Laboratories Inc.
- Zoetis
- Merck & Co. Inc.
- Phibro Animal Health Corporation
- KBNP
- HIPRA
- Nisseiken Co. Ltd.
- Elanco
- CAVAC
- Vaxxinova International BV
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.41 Billion |
| Forecasted Market Value ( USD | $ 1.01 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
